GoodRx Holdings (GDRX) Receivables (2019 - 2026)

GoodRx Holdings has disclosed Receivables across 8 years of filings, most recently posting $194.0 million for Q2 2026.

• In Q2 2026, Receivables rose 2.65% year-over-year to $194.0 million; the TTM figure through Jun 2026 stood at $194.0 million (up 2.65% YoY), while the FY2025 annual figure was $247.6 million, up 69.7% from the prior year.
• Receivables came in at $194.0 million for Q2 2026 at GoodRx Holdings, down from $244.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $247.6 million in Q4 2025 to a low of $116.4 million in Q1 2023.
• Average Receivables over 5 years is $156.2 million, with a median of $144.2 million recorded in 2023.
• Year-over-year, Receivables dropped 5.55% in 2023 and jumped 69.7% in 2025.
• Over 5 years, Receivables stood at $117.1 million in 2022, then gained by 22.59% to $143.6 million in 2023, then climbed by 1.62% to $145.9 million in 2024, then jumped by 69.7% to $247.6 million in 2025, then retreated by 21.65% to $194.0 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $194.0 million in Q2 2026, $244.6 million in Q1 2026, and $247.6 million in Q4 2025.